Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment

N/ACitations
Citations of this article
70Readers
Mendeley users who have this article in their library.

Abstract

Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality worldwide. CRC mortality results almost exclusively from metastatic disease (mCRC) for which systemic chemotherapy is often a preferred therapeutic option. Biomarker-based stratification of mCRC enables the use of precision therapy based on individual tumor mutational profiles. Activating mutations in the RAS/RAF/MAPK pathway downstream of EGFR signaling have, until recently, limited the use of EGFR-targeted therapies for mCRC; however, the development of anti-RAS and anti-RAF therapies together with improved strategies to limit compensatory signaling pathways is resulting in improved survival rates in several highly lethal mCRC sub-types (e.g., BRAF-mutant). The use of fluoropyrimidine (FP)-based chemotherapy regimens to treat mCRC continues to evolve contributing to improved long-term survival. Future advances in chemotherapy for mCRC will need to position development relative to the advances made in precision oncology.

Cite

CITATION STYLE

APA

Gmeiner, W. H. (2024, March 1). Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. Cancers. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/cancers16051029

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free